Advanced Cancer Therapeutics PFK-158 Featured in CEO/CFO Magazine; Announces MD Anderson and UT Health Science Center San Antonio Added as Clinical Trial Sites
Summary
According to Mr. Riggs, “We were pleased to partner with MD Anderson and UT Health Science Center in San Antonio to expand the number of clinical trial sites for PFK-158.PFK-158 is a first-in-man, novel anti-cancer drug that prevents tumor cells from using glucose as a fuel source for tumor survival, growth and metastasis and is currently in a Phase 1 clinical study in the US.” In November 2014, PFK-158 was chosen by Informa and Kantar Health as one of the “2014 Top 10 Most Interesting Oncology Projects to Watch.” PFK-158 is a small molecule that inactivates a novel cancer metabolism target never before examined in human clinical trials.Louisville, KY, December 17, 2014 --( PR.com )-- Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, has been featured in the December 15, 2014 issue of CEO/CFO Magazine in which ACT President and CEO Randall B. Riggs discusses PFK-158, a first-in-man/first-in-class inhibitor of PFKFB3, an enzyme that controls glycolysis and that is overexpressed in most hematological and solid tumors.To read a full copy of the interview, please visit:https://ceocfointerviews.com/interviews/AdvancedCancer14.htmIn the article, Mr. Riggs announces that two new clinical trial sites have been added: MD Anderson Cancer Center in Houston, Texas and the University of Texas Health Science Center in San Antonio, Texas.PFK-158 is a first-in-man, novel anti-cancer drug that prevents tumor cells from using glucose as a fuel source for tumor survival, growth and metastasis and is currently in a Phase 1 clinical study in the US.” In November 2014, PFK-158 was chosen by Informa and Kantar Health as one of the “2014 Top 10 Most Interesting Oncology Projects to Watch.”PFK-158 is a small molecule that inactivates a novel cancer metabolism target never before examined in human clinical trials.Last spring, the U.S. Food and Drug Administration (FDA) approved Phase 1 dose escalation study that is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as prostate, lung, ovarian, melanoma, breast and pancreatic cancer.PFK-158 is the first 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) inhibitor to undergo clinical trial testing in cancer patients.